The conversation reveals how taxpayers unknowingly fund much of the drug innovation through the NIH, only for Big Pharma to profit from it. By negotiating hidden rebates and inflating costs, these companies manipulate the market, leaving consumers to bear the brunt of exorbitant prices. The discussion sheds light on the complex relationship between government funding, pharmaceutical innovation, and the resulting financial burden on the public.
